As shown in Figure 1A, both the radiopharmaceuticals significantly localized at sites of HCC tissues at 24 h p.i. The uptake of 131I-anti-MIF McAb in HCC tumors was 0.214 ± 0.021%ID/g at 24 h p.i. and retained to 0.086 ± 0.0013%ID/g at 72 h p.i. (n = 8/group). Here, MIF is linked to hepatocellular carcinoma.